Sign In
Buy ALT
$2.87
-0.0300 (-1.03%)
At Close: Jun 03, 2026
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
01:49pm, Thursday, 16'th Feb 2023
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.
Zoetis' (ZTS) Q4 Earnings in Line With Estimates, Revenues Beat
04:57pm, Tuesday, 14'th Feb 2023 Zacks Investment Research
Zoetis' (ZTS) fourth-quarter 2022 earnings per share was at par with the Zacks Consensus Estimate, while revenues beat the same. The company provides its financial guidance for 2023.
4 Analysts Have This to Say About Altimmune
04:00pm, Friday, 20'th Jan 2023 Benzinga
Within the last quarter, Altimmune (NASDAQ:ALT) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
0
0
0
Last 30D
1
Teladoc (TDOC) to Reduce Operating Costs, Shares Fall 6.6%
03:43pm, Thursday, 19'th Jan 2023 Zacks Investment Research
Teladoc (TDOC) is likely to book a $17-million charge in 2023, of which, around $10 million will come from staff reduction moves.
Why You Should Keep Acadia Healthcare (ACHC) in Your Portfolio
04:27pm, Tuesday, 17'th Jan 2023 Zacks Investment Research
The constant growth in the senior population is expected to be beneficial for companies like Acadia Healthcare (ACHC) as demand for hospital services rises.
Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe
04:21pm, Tuesday, 17'th Jan 2023 Zacks Investment Research
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
7 Small-Cap Stocks with Big Growth Potential in 2023
07:50am, Tuesday, 10'th Jan 2023
Some of the greatest opportunities can be found in these small-cap stocks to buy. For one, a good number of small-cap stocks are severely undervalued.
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
12:30pm, Wednesday, 04'th Jan 2023 GlobeNewswire Inc.
GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder,
Altimmune Appoints Raymond Jordt as Chief Business Officer
12:30pm, Wednesday, 04'th Jan 2023 GlobeNewswire Inc.
Mr. Jordt brings over 25 years of industry experience in corporate strategy and business development Mr. Jordt brings over 25 years of industry experience in corporate strategy and business developmen
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session
06:51pm, Wednesday, 21'st Dec 2022 Benzinga
Gainers
Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical machini
Altimmune Stock Skyrockets on NAFLD Drug Trial Data
02:30pm, Wednesday, 21'st Dec 2022
Altimmune Inc (NASDAQ:ALT) and SINTX Technologies Inc (NASDAQ:SINT) are trending today.
Lucid Group, Verona Pharma And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
12:56pm, Tuesday, 20'th Dec 2022 Benzinga
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Verona Pharma plc (NASDAQ: VRNA) shares jumped 39.3% to $18.80 in pre-m
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
12:00pm, Tuesday, 20'th Dec 2022 GlobeNewswire Inc.
GAITHERSBURG, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced topline results from its 24-week (12-week extension) t
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
06:38pm, Monday, 19'th Dec 2022 Benzinga
Gainers
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Axcella H
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
06:21pm, Sunday, 18'th Dec 2022
Some of the hottest biotech stocks are safe and recession-proof. After all, we can't stop people from aging – at least, not yet.
